pentobarbital will reduce the extent or effect of gefitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or influence of abemaciclib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration of abemaciclib with sturdy CYP3A4 inducers decreases plasma concentration of abemaciclib and its metabolites.
With therapeutic doses of TCAs, barbiturates raise metabolism and reduce blood concentrations of TCAs.
Reserve concomitant prescribing of such drugs in patients for whom other treatment method alternatives are insufficient. Restrict dosages and durations on the bare minimum necessary. Monitor intently for indications of respiratory depression and sedation.
If inducer is discontinued, contemplate oliceridine dosage reduction and observe for signs of respiratory depression.
Watch Intently (1)pentobarbital will minimize the extent or impact of mifepristone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. CYP3A4 inducers have not been examined, coadministration not suggested by producer
pentobarbital will lower the level or influence of flurbiprofen by influencing hepatic enzyme CYP2C9/10 metabolism. Small/Importance Unfamiliar.
pentobarbital will reduce the level or impact of methylprednisolone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Contraindicated (1)pentobarbital will decrease the level or effect of doravirine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
buprenorphine transdermal and pentobarbital both equally maximize sedation. Steer clear of here or Use Alternate Drug. Limit use to sufferers for whom substitute therapy selections are insufficient
pentobarbital will reduce the extent or effect of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration. Strong or moderate CYP3A inducers may perhaps lower cobimetinib systemic publicity by >eighty% and lessen its efficacy.
Monitor Closely (one)pentobarbital will reduce the level or result of glecaprevir/pibrentasvir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the extent or outcome of darifenacin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will reduce the extent or influence of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Lack of, or diminished response to tofacitinib may well take place when coadministered with powerful CYP3A4 inducers